Aseptic Processing and Cleanroom Grades: The Peptide Vial Fill Environment No COA Reports

Peptide aseptic processing is the set of environmental and procedural controls that determine whether a filled vial is sterile, and none of it appears on a certificate of analysis. A COA reports what a laboratory found in a finished sample. The cleanroom grade, the airflow velocity, the viable monitoring record and the aseptic process simulation history behind that sample are separate documents that research peptide suppliers almost never publish.

This distinction matters because sterility is a process attribute, not a test result. A passing sterility test on a small sample cannot establish that a batch is sterile, a statistical limitation covered in detail in our discussion of sterility and bioburden testing in research peptide quality control. What establishes sterility assurance is the environment the product was exposed to while its container was open. The regulatory framework describing that environment is EU GMP Annex 1, revised on 22 August 2022 and in operation from 25 August 2023, with the lyophilizer loading provisions in point 8.123 deferred to 25 August 2024.

What Aseptic Processing Actually Controls

Aseptic processing means combining a sterilised product, a sterilised container and a sterilised closure in an environment engineered to prevent microbial ingress. There is no terminal sterilisation step to correct an error. Every unit of assurance comes from the environment and the behaviour of the operators inside it.

Annex 1 defines four cleanliness grades. Grade A is the critical zone where the product and open components are exposed, typically an isolator, a restricted access barrier system or a unidirectional airflow hood at the point of fill. Grade B is the background cleanroom surrounding a Grade A zone when that zone is not enclosed in an isolator. Grades C and D are lower classified areas for preparation steps that do not expose the product. The 2022 revision requires a documented Contamination Control Strategy spanning the whole facility rather than a collection of individually compliant rooms.

The guidance also specifies a homogeneous air speed of 0.36 to 0.54 m/s as a guidance value at the working position for unidirectional airflow systems, with airflow visualisation studies required to correlate with the measured velocity. That number is a useful test of whether a supplier claiming a sterile fill has an actual qualified line or a laminar flow bench in a general laboratory.

Cleanroom Grades and What Classification Measures

Total particle limits

Classification under ISO 14644 Part 1 counts non-viable particles at two size thresholds. Annex 1 Table 1 sets the maximum permitted concentration of particles 0.5 micrometres and larger at 3 520 per cubic metre for Grade A in both the at rest and in operation states. Grade B permits the same 3 520 at rest but relaxes to 352 000 in operation. Grade C allows 352 000 at rest and 3 520 000 in operation. Grade D is set at 3 520 000 at rest with in operation limits left to the manufacturer to justify from risk assessment and routine data.

The at rest and in operation distinction is the part most often lost in marketing copy. At rest means the room is complete and the air handling is running but no personnel are present and the equipment is idle. In operation means the full complement of personnel is present performing or simulating routine work. A facility that only ever classifies at rest has measured an empty room. Annex 1 further requires that at rest limits be restored after a clean up period, with a guidance value of less than 20 minutes.

Viable contamination limits

Table 2 of Annex 1 sets microbial limits during qualification. Grade A is specified as no growth. Grade B permits 10 CFU per cubic metre by active air sample, 5 CFU per 90 mm settle plate over a maximum four hour exposure and 5 CFU per 55 mm contact plate. Grade C moves to 100, 50 and 25 respectively. Grade D permits 200, 100 and 50. Table 6 adds a routine action limit of 5 CFU per glove for five fingers on both hands in Grade B, and repeats the no growth expectation for Grade A with an explicit note that any growth in Grade A should trigger an investigation.

The 2008 version of Annex 1 expressed the Grade A microbial limit as fewer than 1 CFU, which practitioners read as an average permitting rare excursions. The 2022 revision removed that ambiguity by stating no growth. This is a meaningful tightening, because it converts a tolerance into an investigation trigger.

Key Research Findings

• Napoli et al., BMC Public Health, 2012;12:594 measured microbial air contamination in operating rooms using simultaneous active and passive sampling. Mean total viable count at rest was 12.4 CFU/m3 by active sampling (SD 12.1, range 0 to 56) against 722.5 CFU/m2/h by settle plate (SD 1035.5, range 0 to 4718.5), across 32 rooms.
• In the same study, mean in operational total viable count rose to 93.8 CFU/m3 (SD 52.69, range 22 to 256) and 10 496.5 CFU/m2/h (SD 7460.5, range 1415.5 to 25 479.7) across 19 rooms. Human activity increased the active air count roughly 7.6 fold and the settle plate count roughly 14.5 fold.
• Napoli et al. found the two methods correlated strongly, with Spearman coefficients of 0.96 at rest and 0.99 in operational, and regression fits of R2 = 0.84 (F = 154.1, p < 0.01) and R2 = 0.82 (F = 76.3, p < 0.01) respectively. The methods track each other but report in different units and are not interchangeable against a single numeric limit.
• Austin and Elia, Journal of Pharmacy and Pharmaceutical Sciences, 2009;12(2):233-242 pooled 18 studies covering 7 293 aseptically prepared units. Contamination was lower in a pharmaceutical controlled environment than a clinical one for individual preparations (3.3% versus 6.8%, p = 0.051) and markedly lower for batch preparations (0.05% versus 8%, p < 0.001).
• Krämer et al., Journal of Oncology Pharmacy Practice, 2016;22(2):195-204 ran 1 000 media fill units over 18 working days, 500 prepared by a robotic system and 500 manually in cytotoxic workbenches in the same cleanroom. None showed turbidity after four weeks of incubation, while fingertip contact plates exceeded the Grade A limit several times during manual preparation and never during automated preparation.

Aseptic Process Simulation and Why Zero Is the Target

An aseptic process simulation, commonly called a media fill, substitutes a microbiological growth medium for the product and runs the line as it would run in production, including the authorised interventions operators actually perform. The filled units are agitated to wet all interior surfaces, incubated, and inspected for turbidity.

Annex 1 paragraph 9.46 states that the target should be zero growth and that any contaminated unit should result in a failed simulation, an investigation into root cause, and normally a minimum of three successful consecutive repeat runs before the process is considered back in control. Products manufactured on that line since the last successful simulation must be quarantined pending resolution. This replaced the older convention, still quoted in some vendor material, of a 0.1 percent contamination rate demonstrated across roughly 3 000 units at 95 percent confidence.

The scale requirements are specific. Paragraph 9.40 states that typically a minimum of 5 000 to 10 000 units are filled, and that for production batches under 5 000 units the simulation should at least equal the production batch size. Paragraph 9.38 requires at least three consecutive satisfactory simulations at initial validation covering all working shifts, repetition approximately every six months for each process, line and shift, and participation by each operator in at least one successful simulation annually. Paragraph 9.39 tightens this further for manual operations, requiring three consecutive successful simulations per operator at initial qualification.

A supplier filling a few hundred vials at a time has a defensible path here, because the guidance scales the simulation to the batch. What is not defensible is having no simulation record at all, which is the ordinary condition of a research peptide operation that repackages bulk material.

What Environmental Monitoring Data Actually Represent

The Napoli data illustrate why a single monitoring number is hard to interpret in isolation. Settle plates measure deposition over time in CFU per square metre per hour. Active samplers measure concentration in CFU per cubic metre. The two correlated tightly in that study, but the magnitudes differ by orders of magnitude because the quantities are physically different.

Settle plates also have a known collection bias. Because they rely on gravitational deposition, their capture efficiency falls sharply for smaller particles, particularly under the downward airflow of a Grade A zone where fine particles are swept away rather than settling. That is precisely why Annex 1 Table 2 requires air sample, settle plate and contact plate methods together for a given grade, and states in Note 1 that omitting any tabulated method requires justification.

The seven to fifteen fold increase Napoli et al. recorded between the at rest and in operational states is the single most useful number in this literature for evaluating a supplier claim. It quantifies the fact that people are the contamination source. A facility that reports only at rest monitoring has measured the condition under which the product is never actually exposed.

Lyophilization Widens the Exposure Window

Freeze drying is the standard presentation for research peptides because the solid state suppresses hydrolysis and aggregation, as covered in our review of lyophilization science and excipient selection. It also creates the longest period of container exposure in the entire process. Vials are transported to the lyophilizer with stoppers partially seated, held under vacuum and controlled shelf temperature for many hours, then stoppered inside the chamber and unloaded.

Annex 1 point 8.122 requires that lyophilizer sterilisation and the hold time between sterilisation and use be validated and challenged during the aseptic process simulation. Point 8.123, the provision deferred to August 2024, addresses the design of lyophilizers and their transfer and loading areas to minimise operator intervention. Partially stoppered vials in transit are the highest risk moment in an aseptic peptide operation, and it is the moment least visible to anyone reading a finished product certificate.

Why None of This Appears on a Certificate of Analysis

A certificate of analysis is a record of testing performed on a sample. It can carry HPLC area percent, mass confirmation, water content, endotoxin, and where the supplier pays for it, a sterility result. It cannot carry a cleanroom classification report, a viable monitoring trend, an aseptic process simulation record or an intervention log, because those are facility documents belonging to the filler, not analytical results belonging to the batch.

This is the same structural gap that applies to container closure integrity. The certificate describes the contents. It does not describe the barrier around the contents or the room in which that barrier was closed. A researcher evaluating a supplier should treat a purity number and an environmental claim as two separate questions requiring two separate forms of evidence. Our published batch certificates report third party analytical results and should be read for what they are, analytical data, rather than as a statement about manufacturing environment.

The practical question to put to any supplier claiming sterile or aseptically filled product is narrow and answerable. What grade is the fill zone, was it classified in operation as well as at rest, when was the most recent aseptic process simulation, how many units did it contain, and what was the result. A supplier that cannot answer those five questions is describing an aspiration rather than a qualified process.

Limitations and Open Questions

The contamination data cited here come from hospital pharmacy and operating room settings, not from research peptide filling lines, because the latter are almost entirely unpublished. Austin and Elia explicitly noted that the studies they pooled used variable methodology and were not judged to be of high quality, and the wide confidence intervals in that literature reflect real heterogeneity between sites. The Krämer study reported zero contaminated units out of 1 000, which is consistent with a well controlled process but has limited statistical power to distinguish a very low contamination rate from a true zero.

Annex 1 is a European guideline and is not directly enforceable against a Canadian research chemical supplier. It is cited here as the most detailed publicly available specification of what a controlled aseptic environment requires, and therefore as a benchmark against which supplier claims can be measured, not as a regulatory obligation that applies to research use material.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.